Twist Bioscience (TWST) Enterprise Value (2018 - 2026)

Twist Bioscience has disclosed Enterprise Value across 9 years of filings, most recently posting -$171.7 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 33.23% year-over-year to -$171.7 million; the TTM figure through Mar 2026 stood at -$171.7 million (up 33.23% YoY), while the FY2025 annual figure was -$232.4 million, up 15.91% from the prior year.
• Enterprise Value rose to -$171.7 million in Q1 2026, from -$198.0 million in the prior quarter.
• Over the last five years, Enterprise Value for TWST reached as high as -$171.7 million in Q1 2026 and fell as low as -$573.9 million in Q1 2022.
• The 5-year median for Enterprise Value is -$293.3 million (2024), against an average of -$334.0 million.
• Annual changes were most pronounced in 2022 — Enterprise Value plunged 45.34% — and 2023, when it jumped 33.38%.
• A 5-year view of Enterprise Value shows it stood at -$438.7 million in 2022, then increased by 29.08% to -$311.1 million in 2023, then rose by 12.96% to -$270.8 million in 2024, then advanced by 26.91% to -$198.0 million in 2025, then advanced by 13.26% to -$171.7 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$171.7 million, -$198.0 million, and -$232.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.